Study of Tofacitinib in Refractory Dermatomyositis
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain preliminary data regarding the safety and efficacy of
Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory
dermatomyositis.